Compound 15
2-chloro-N-(3-(1-(1-(pentan-2-yl)piperidin-4-yl)-3-(3-(trifluoromethyl)phenyl)ureido)propyl)acetamide
From: Blocking an N-terminal acetylation–dependent protein interaction inhibits an E3 ligase
Synthetic procedure: See article for the definitive version of this procedure and for full experimental details.
Average Purity (ELSD/UV): 95%.1H NMR (500 MHz, Chloroform-d) δ 7.85 (s, 1H), 7.67 (d, J = 8.3 Hz, 1H), 7.53 (bs, 1H), 7.44 – 7.31 (m, 2H), 7.28 (d, J = 6.9 Hz, 1H), 4.23 (bs, 1H), 4.08 (s, 2H), 3.41 (t, J = 7.9 Hz, 2H), 3.35 (q, J = 6.1 Hz, 2H), 3.20 – 3.10 (m, 2H), 2.95 (bs, 1H), 2.74 – 2.54 (m, 2H), 2.25 – 2.10 (m, 2H), 2.00 – 1.77 (m, 4H), 1.75 – 1.60 (m, 1H), 1.50 – 1.26 (m, 3H), 1.17 (d, J = 6.5 Hz, 3H), 0.95 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 167.3, 155.1, 139.9, 131.0 (q, J = 32.1 Hz), 129.2, 123.8 (q, J = 268.5 Hz), 123.2, 119.4 (q, J = 3.9 Hz), 116.9 (q, J = 3.9 Hz), 60.5, 51.9, 49.2, 47.1, 42.6, 40.1, 37.6, 34.1, 30.3, 28.6, 19.8, 13.9, 13.8. LRMS (APCI+) m/z calcd for C23H35ClF3N4O2 [M+H]+ 491.2, found 491.1.
- PubChemID:
-
336287082
- MDL Molfile:
- ChemDraw:
